- Home
- THM vs ALLO Comparison
THM vs ALLO Comparison
Compare THM & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THM | ALLO |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 597.7M |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | THM | ALLO |
|---|---|---|
| Price | $2.60 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 680.1K | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | $280.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $1.04 |
| 52 Week High | $3.65 | $4.46 |
Technical Indicators
Market Signals| Indicator | THM | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 35.42 |
| Support Level | $2.54 | $1.59 |
| Resistance Level | $2.76 | $1.92 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 86.11 | 6.58 |
Price Performance
Historical ComparisonAbout THM International Tower Hill Mines Ltd. (Canada)
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).